- ICH GCP
- Registre américain des essais cliniques
- Essai clinique NCT07670923
Comparison of Hemodynamics and Respiratory Function Between Ciprofol and Propofol in Elderly Patients Undergoing Non-intubated General Anesthesia
Aperçu de l'étude
Statut
Intervention / Traitement
Description détaillée
Inclusion Criteria
- Patients scheduled for elective non-intubated general anesthesia
- Age ranging from 65 to 80 years old
- American Society of Anesthesiologists (ASA) physical status class I-III
- Written informed consent signed by the patient or legal guardian
Exclusion Criteria
- Confirmed allergy to propofol, ciprofol or their excipients
- Severe cardiovascular diseases (uncontrolled hypertension, heart failure, severe arrhythmia, etc.)
- Severe respiratory diseases (chronic obstructive pulmonary disease, obstructive sleep apnea syndrome, etc.)
- Severe hepatic or renal insufficiency
- Long-term regular use of sedatives or opioids
- Baseline bradycardia (HR < 50 beats/min) or hypoxemia (SpO₂ < 90%) Elimination Criteria
1. Patients with allergic reactions to study drugs or other severe complications during the trial
2. Severe hypoxemia requiring emergency endotracheal intubation
3. Severe hemodynamic instability occurring during induction
4. Incomplete monitoring data caused by equipment malfunction Randomization and Group Allocation A total of 108 eligible elderly patients undergoing elective non-intubated general anesthesia at the Cardiovascular and Cerebrovascular Disease Hospital, General Hospital of Ningxia Medical University will be recruited. A computer-generated random number sequence will allocate subjects at a 1:1 ratio into the ciprofol group (Group C) and the propofol group (Group P).
Observation Indicators
Baseline Demographic Data
Gender, age, height, weight, BMI, ASA classification, smoking history, alcohol consumption, underlying diseases, Modified Mallampati score, thyromental distance, snoring history, etc.
Primary Observation Indicators
Hemodynamic parameters (Heart rate (HR), systolic blood pressure (SBP), diastolic blood pressure (DBP), mean arterial pressure (MAP), cardiac output (CO), stroke volume (SV), systemic vascular resistance (SVR)) and respiratory parameters (peripheral oxygen saturation (SpO₂), respiratory rate (RR), end-tidal carbon dioxide (EtCO₂)) will be recorded at baseline, loss of consciousness, 30 s, 1 min, 2 min, 3 min, 4 min and 5 min after loss of consciousness.
Secondary Observation Indicators
- Baseline BIS value and minimum BIS value during induction
- Total induction dosage, induction time (from drug administration to MOAA/S ≤ 1), recovery time (from last drug administration to MOAA/S = 5)
- Incidence of adverse reactions: injection pain, involuntary movement, hiccup, hypotension, bradycardia, hypoventilation, apnea, hypoxemia, etc.
Anesthetic Protocol
All patients fast for 8 hours and abstain from clear liquids for 4 hours preoperatively. After entering the operating room, oxygen inhalation is initiated, upper limb venous access is established, and monitors including pulse oximetry, sidestream PETCO₂ monitor, continuous non-invasive arterial blood pressure monitor and bispectral index (BIS) monitor are connected.
Midazolam 0.01 mg/kg is administered intravenously first; stable circulatory and respiratory readings thereafter serve as baseline values. Ciprofol or propofol is then infused intravenously at 10 mL/min. Sedation depth is assessed every 5 seconds via MOAA/S scale; drug infusion is stopped once MOAA/S ≤ 1 (loss of consciousness). The total induction dose is recorded. All hemodynamic and respiratory indicators are documented at predefined time points.
Anesthesiologists may supplement 1/3 of the initial induction dose if the patient shows eye opening, verbal response or body movement, with an interval of at least 1 minute between supplemental doses.
Rescue Management Protocols
- Hypotension (SBP < 90 mmHg or MAP decreased by >20% from baseline lasting >2 min): ephedrine 6 mg IV
- Severe bradycardia (HR < 45 beats/min lasting >30 s): atropine 0.5 mg IV
- Hypoventilation (RR < 8 bpm, PETCO₂ less than half baseline or PETCO₂ ≥45 mmHg lasting >30 s)
- Apnea (no thoracic movement or flat PETCO₂ waveform lasting >10 s)
- Hypoxemia (SpO₂ < 93%) / severe hypoxemia (SpO₂ < 85%) For respiratory compromise, jaw thrust, increased oxygen flow or mask-assisted ventilation will be applied; emergency endotracheal intubation will be performed if necessary.
Type d'étude
Inscription (Estimé)
Phase
- Phase 4
Contacts et emplacements
Coordonnées de l'étude
- Nom: Hanxiang Ma Ma, master
- Numéro de téléphone: 13519591508
- E-mail: mahanxiang@hotmail.com
Sauvegarde des contacts de l'étude
- Nom: LI Mo Mo, Bachelor
- Numéro de téléphone: 17752025907
- E-mail: ml185030153@163.com
Lieux d'étude
-
-
Ningxia
-
Yinchuan, Ningxia, Chine, 750000
- Recrutement
- Cardiovascular and Cerebrovascular Disease Hospital, General Hospital of Ningxia Medical University
-
-
Critères de participation
Critère d'éligibilité
Âges éligibles pour étudier
- Adulte plus âgé
Accepte les volontaires sains
La description
Inclusion Criteria:
- Patients scheduled for elective non-intubated general anesthesia
- Age ranging from 65 to 80 years old
- American Society of Anesthesiologists (ASA) physical status class I-III
- Written informed consent signed by the patient or legal guardian
Exclusion Criteria:
- Confirmed allergy to propofol, ciprofol or their excipients
- Severe cardiovascular diseases (uncontrolled hypertension, heart failure, severe arrhythmia, etc.)
- Severe respiratory diseases (chronic obstructive pulmonary disease, obstructive sleep apnea syndrome, etc.)
- Severe hepatic or renal insufficiency
- Long-term regular use of sedatives or opioids
- Baseline bradycardia (HR < 50 beats/min) or hypoxemia (SpO₂ < 90%)
Plan d'étude
Comment l'étude est-elle conçue ?
Détails de conception
- Objectif principal: Traitement
- Répartition: Randomisé
- Modèle interventionnel: Affectation parallèle
- Masquage: Quadruple
Armes et Interventions
Groupe de participants / Bras |
Intervention / Traitement |
|---|---|
|
Expérimental: Ciprofol treatment group
This group plans to enroll a total of 54 elderly patients aged 65-80 who will undergo brief procedures without intubation, using spontaneous respiration under general anesthesia.
The intravenous infusion of cyclopropane hydrochloride injection will be administered at a constant rate of 10 ml/min.
The administration will cease when the MOAA/S score is ≤1.
Throughout the procedure, hemodynamic parameters (HR, SBP, DBP, MAP, CO, SV,SVR), and respiratory parameters (SpO₂, respiratory rate (RR), PETCO₂), and various anesthetic adverse reactions will be monitored within the first 5 minutes after induction.
The safety of the medication will be evaluated in comparison with the control group
|
Intravenous administration, injection rate of 10 ml/min, continuous and uniform infusion until the patient's MOAA/S sedation score is ≤1 point.
This is used for the induction of general anesthesia in short-duration medical procedures for elderly individuals aged 65-80 without intubation and with spontaneous respiration
|
|
Comparateur actif: Propofol Control group
This study aims to enroll 54 elderly patients aged 65-80 with short procedures and no need for intubation, who will receive propofol intravenously at a constant rate of 10 ml/min until their MOAA/S score drops to ≤1 point.
Circulatory and respiratory parameters, as well as adverse events, will be recorded simultaneously 5 minutes after induction.
This will allow for a parallel comparison of the two medications' effects on the circulatory and respiratory systems of elderly patients with the propofol control group.
|
Intravenous administration, injection rate of 10 ml/min, continuous and uniform infusion until the patient's MOAA/S sedation score is ≤1 point.
This is used for the induction of general anesthesia in short-duration medical procedures for elderly individuals aged 65-80 without intubation and with spontaneous respiration
|
Que mesure l'étude ?
Principaux critères de jugement
Mesure des résultats |
Description de la mesure |
Délai |
|---|---|---|
|
Comparison of hemodynamic and respiratory function changes within 5 minutes of anesthesia induction
Délai: 5 minutes after induction of anesthesia
|
The primary objective of this study was to evaluate the degree of circulatory and respiratory suppression induced by two types of anesthesia drugs in elderly patients.
Continuous, non-invasive monitoring was conducted on the baseline conditions before administration for patients aged 65 to 80 undergoing short procedures without intubation and with spontaneous respiration under general anesthesia.
Additionally, measurements were taken at 1 minute, 2 minutes, 3 minutes, 4 minutes, and 5 minutes after induction to assess circulatory and respiratory functions.
Statistical analysis was performed to compare the changes in Heart rate, systolic blood pressure, diastolic blood pressure, mean arterial pressure, cardiac output , stroke volume, systemic vascular resistance , peripheral oxygen saturation, respiratory rate , end-tidal carbon dioxid within the 5-minute induction period.
A comprehensive assessment of the dual safety of circulatory and respiratory systems was conducted
|
5 minutes after induction of anesthesia
|
Mesures de résultats secondaires
Mesure des résultats |
Description de la mesure |
Délai |
|---|---|---|
|
Brain electrical activity sedation depth (BIS)
Délai: 5 minutes after induction of anesthesia
|
lowest BIS value throughout the induction process, BIS value immediately upon loss of consciousness.
|
5 minutes after induction of anesthesia
|
|
incidence of induction period circulatory/respiratory adverse events
Délai: 5 minutes after induction of anesthesia
|
Proportion of adverse events, including low blood pressure, bradycardia, inadequate ventilation, apnea, and hypoxemia, occurring within 5 minutes of induction
|
5 minutes after induction of anesthesia
|
Collaborateurs et enquêteurs
Dates d'enregistrement des études
Dates principales de l'étude
Début de l'étude (Réel)
Achèvement primaire (Estimé)
Achèvement de l'étude (Estimé)
Dates d'inscription aux études
Première soumission
Première soumission répondant aux critères de contrôle qualité
Première publication (Réel)
Mises à jour des dossiers d'étude
Dernière mise à jour publiée (Réel)
Dernière mise à jour soumise répondant aux critères de contrôle qualité
Dernière vérification
Plus d'information
Termes liés à cette étude
Mots clés
Termes MeSH pertinents supplémentaires
- Processus pathologiques
- Maladies des voies respiratoires
- Troubles respiratoires
- Conditions pathologiques, signes et symptômes
- Aspiration respiratoire
- Produits chimiques organiques
- Hydrocarbures
- Hydrocarbures, cyclique
- Hydrocarbures, aromatique
- Phénols
- Dérivés de benzène
- Propofol
- (2- (1R) -1-cyclopropyl) éthyl-6-isopropyl-phénol
Autres numéros d'identification d'étude
- Li Mo-2026-06-22
Informations sur les médicaments et les dispositifs, documents d'étude
Étudie un produit pharmaceutique réglementé par la FDA américaine
Étudie un produit d'appareil réglementé par la FDA américaine
Ces informations ont été extraites directement du site Web clinicaltrials.gov sans aucune modification. Si vous avez des demandes de modification, de suppression ou de mise à jour des détails de votre étude, veuillez contacter register@clinicaltrials.gov. Dès qu'un changement est mis en œuvre sur clinicaltrials.gov, il sera également mis à jour automatiquement sur notre site Web .